No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Benefix market is a subset of the hematological drug market, which focuses on treatments for blood-related diseases and disorders. Benefix is a recombinant form of Factor IX, a protein that helps the body form blood clots. It is used to treat and prevent bleeding episodes in people with hemophilia B, a genetic disorder that impairs the body's ability to form blood clots. Benefix is administered intravenously or subcutaneously, and is available in both single- and multi-dose vials.
Benefix is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is currently marketed by Pfizer, Inc., and is available in more than 70 countries worldwide. Other companies in the Benefix market include Novo Nordisk, Shire, and Bayer. Show Less Read more
